$Hims & Hers Health Inc.(HIMS)$ 🤣 $HIMS just handed BofA’s $28 underperform rating a masterclass in irrelevance, ripping +7.4% to $47.77 while the Street clings to old narratives. FDA vs court battles may decide compounding in theory, but the market’s verdict is clear in practice: breakout through Keltner/Bollinger, EMAs flipping bullish, and buyers pressing higher. Sometimes price is the best cross-examiner.
📢 Don’t miss out! Like, Repost and Follow me for exclusive setups, cutting-edge trends, and insights that move markets 🚀📈 I’m obsessed with hunting down the next big movers and sharing strategies that crush it. Let’s outsmart the market and stack those gains together! 🍀
Trade like a boss! Happy trading ahead, Cheers, BC 📈🚀🍀🍀🍀
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Great article, would you like to share it?